College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.
about
The Anti-Factor Xa Range For Low Molecular Weight Heparin ThromboprophylaxisA systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiencyGuidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolismLaboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulantsParenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesAppropriate enoxaparin dose for venous thromboembolism prophylaxis in patients with extreme obesity.Development of a dosing strategy for enoxaparin in obese patients.Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis.Monitoring of anticoagulant therapy in heart disease: considerations for the current assays.Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.Prevention and treatment of venous thromboembolism in the elderly patientCase files of the Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, AZ: a non-warfarin anticoagulant overdose.Policies and practices in haemostasis testing among laboratories in Croatia: a survey on behalf of a Working Group for Laboratory Coagulation of the Croatian Society of Medical Biochemistry and Laboratory Medicine.Clinical Feasibility of Monitoring Enoxaparin Anti-Xa Concentrations: Are We Getting It Right?
P2860
Q26770822-DCF08006-1DA0-4160-A838-C2A486DF3836Q26995027-64092FAB-918C-417F-BFE2-AFEAF55F9DCEQ28079081-8C5ADAEA-F7B7-4624-9668-ADC909F97BDDQ33349870-7013A062-E784-4A66-9F51-34A9B37C96B1Q33399576-B58E5765-4463-4D7F-97BB-4945D07117DCQ34612869-147E90EA-B9AB-4A1D-8B0A-A47C14D9F1F7Q35825624-8908E765-663F-424A-9424-095587DD6105Q35827649-EDAC8E2F-4DCE-4A55-A0F1-C52D3485EF43Q36205646-9F19FFE3-4F48-4B5D-A57C-51F9A2E51654Q36304924-8EC5088F-FF3E-489B-B872-104E2331A0B4Q36748915-52DC7898-9749-42A6-B83E-AA6C3757A975Q37017407-7E900572-28A8-4010-8431-90BEB878F7D2Q37624544-B75DBB76-CADD-4C5B-B7DA-9548B60D86C5Q37739758-652BA3C3-FEE4-496E-B2B2-97FA319A2465Q50323429-C3E0303E-E19D-4698-A8E4-9040FA0EC260
P2860
College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
College of American Pathologis ...... ted compounds, and argatroban.
@en
College of American Pathologis ...... ted compounds, and argatroban.
@nl
type
label
College of American Pathologis ...... ted compounds, and argatroban.
@en
College of American Pathologis ...... ted compounds, and argatroban.
@nl
prefLabel
College of American Pathologis ...... ted compounds, and argatroban.
@en
College of American Pathologis ...... ted compounds, and argatroban.
@nl
P2093
P1476
College of American Pathologis ...... ated compounds, and argatroban
@en
P2093
E M Van Cott
M Laposata
R C Sosolik
S H Goodnight
T W Barrowcliffe
P304
P577
1998-09-01T00:00:00Z